Singapore markets closed

ABBV Jan 2025 170.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
9.650.00 (0.00%)
As of 01:11PM EST. Market open.
Full screen
Previous close9.65
Expiry date2025-01-17
Day's range9.63 - 9.65
Contract rangeN/A
Open interest422
  • Reuters

    Abbvie plans to lift $2 billion cap on deals - WSJ

    Chief Executive Officer Richard Gonzalez said the company now has the capacity "to do more", in an interview with WSJ that was published on Monday. Abbvie is hoping to replace the loss of revenue from Humira through its newer immunology drugs Skyrizi and Rinvoqn, and has forecast sales of over $21 billion from the two products in 2027.

  • Motley Fool

    2 Stocks Down More Than 6% to Buy Right Now

    In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adria Cimino and Keith Speights talk about why these two stocks actually make great buys right now. Adria Cimino (Johnson & Johnson): J&J may have disappointed investors when it reported fourth-quarter earnings on Jan. 24.

  • Motley Fool

    3 Unstoppable Dividend Stocks to Buy in February

    Any time is a good time to buy solid dividend stocks. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). David Jagielski (Abbott Laboratories):  One dividend stock that should be attractive to long-term investors is Abbott Laboratories.